FDG PET in the management of lymphoma: A clinical perspective

European Journal of Nuclear Medicine

Volumn 29, Issue 4, 2002, Pages 449-451

  Hoskin, P J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036207008     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-001-0755-4     Document Type: Editorial

References (17)

1. Flouride-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?
2. 18F] fluoro-2-deoxy-D-glucose: Correlation with CT
3. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma
4. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
5. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
6. Lymphoma: Role of whole body 2-deoxy-2 [F-18] fluoro-D-glucose (FDG) PET in nodal staging
7. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
8. Positron emission tomography with fluorine-19-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment
9. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
10. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease
11. PET-FDG whole-body imaging in staging Hodgkin's disease: Comparison to conventional imaging
12. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma
13. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
14. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution
15. 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
16. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non Hodgkin's lymphoma - Comparison with CT
17. 18F] FDG-PET a valid alternative to conventional diagnostic methods?